web analytics
Pubblicità

di Giancarlo Nicoli

Commentary and table pounding stock ideas into the year 2011 and beyond

Filed Under Il Rosso e il Verde, Investimenti | Comments Off on Commentary and table pounding stock ideas into the year 2011 and beyond

Graph represents 'ahrahr' (which is me) CAPS performance as on Fool.com

ahrahr (99.30)

ahrahr lost to the market on Friday

Rank: 510 out of 72262

Nothing written below can be construed as an invitation to invest in the detailed securities. Do your own DD.

My opinions FWIW for 2011:

#1 – I think we are in a secular bear market. The secular bear market theory is quite a long subject. You can find more
– here: http://www.amazon.com/gp/product/0471716928?ie=UTF8&t……
– and here: http://www.johnmauldin.com/ (search for “secular bear market”)

#2 – I think we are in a deflationary environment;

#3 – I think it is foolish to try to time the market;

#4 – I think money can be made in the stockmarket nonetheless via some stock picking.

My investment themes:

– I choose reliable, boring, high yield stocks. Study after study shows this is the best way to consistently beat the market.
I own CWH, E, ENEL.MI (Milan stock exchange); ENP, NLY, NRF-B, STON. Also SGI.L (London Stock Exchange) which pays a decent dividend and it is a good growth story for the patient investor.

– I’m a community pharmacist and I think (I’m not being modest here: I hope you understand) I have an edge with biotech/medtech.
I own DNDN (plenty – just a bit less than half my portfolio), SGMO, STXS.

– I own VHC due to the fact that Ming the Merciless (of IV fame) alerted me on that name (!).

With regard to the Maslow hierarchy of needs, so to speak, I think healthcare is just at the top of needs/expectations of all the people.

Now some short commentary. It’s all MHO an YMMV obviously.

– DNDN is by far my favourite stock. Company is doing well. Market for their FDA-approved treatment is large.
They have a huge barrier to entry. No generic competition in sight even after patent expiration. Production process is secret. Competition would have to steal secret or spend years trying to find out how acually Provenge is made. Also, a generic would have to undergo a PIII trial, which in my opinion is unethical.
DNDN process to obtain Provenge is scalable. They have a pipeline with treatments that target several others cancers. DNDN is the history of medicine being made under our eyes.
Market can (and certainly will) go down, so DNDN will. So what? Investment horizon here is not just a couple of years (as I say below) but much more. DNDN is and will be a winner.
They are a five bagger from current stock price over a couple of years in my opinion if the Company executes.

– Next is STXS. They have a magnetic field inducing machine that can safely guide and steer magnetically tipped catheters inside the blood vessels. They have strong IP and strong physicians endorsement. (They should change the BOD really, Company has been poorly guided through a couple of butched share offerings).
Technology is excellent and proven, market is large and expanding, it’s a three bagger within just 2011 if management does well and it’s a five bagger anytime in case they are going to be bought out. Why is a buyout likely? Because there are at least three catheter producers (it’ a 70%+ margin business): JNJ, STJ, Biotronik; and medtech equipment producers: MDT, GE – the one that owns the platform shuts out all the others from the market overnight.
STXS used to be my second largest holding, but it is now the third because…

– I bought SGMO in the low 3s and I’m already sitting on a two bagger.
SGMO holds the Holy Grail wrt DNA manipulation. They can delete, insert, exchange a gene at will, quickly and with accuracy.
Their technology is proven and they are receiving royalties (not many dollars yet) from Sigma Aldrich (Genetic Modified lab rats and mice) and Dow Agro (GM seeds).
They possibly have at hand a cure against HIV/AIDS (Google: “Berlin Patient”).
That alone would be very big.
Applications of their technology are enormous.
SGMO market cap as of friday’s close is $300M. What if HIV/AIDS treatment works? A ten bagger? Naaah! More than that imo obviously.
Those that can handle it might want to check the SGMO board on IV and look for the adenylyl series: How To Cure AIDS.
A link is here:
http://www.investorvillage.com/smbd.asp?mb=1933&mn=21……

– I own VHC because they won the lawsuit against MSFT and because plotinus and ming are here (chech the IV board for plotinus4me and Ming the Merciless). That’ all my dd on that name, since it is well beyond my expertise.

– One last word wrt BMTI, first suggested to me by plotinus. I’m still doing my dd, but at first glance they possibily are much more than a two bagger over the next five years. I think it is wise not to expect a sharp price appreciation over the short term on this name. You never know how a biotech investment is going to play out within a few months. But it is my opinion that this company has legs and it is going to appreciate consistently over the next several years. I will be a buyer with “new” money, either diversification out of a five bagger from current bio-med-tech positions or from savings over the coming months.

Good luck to all and all have this brand new 2011 as a good, happy, safe and prosperous year!


Disclosure. I’m long many of the stocks described above.

This post is not intended to be investment advice of any kind. YMMV. Do your own DD.

Again, this is NOT investment advice.

This is NOT analysis, which is something six-figure equity research types do as full-time jobs for brokerage firms.

This is blogging. I just do like to share ideas.

And, past performance is not indicative of future results.

Post di Giancarlo Nicoli, Appiano Gentile, CO.
Il presente articolo è stato scritto da Giancarlo Nicoli. Le informazioni qui contenute sono state ricavate da fonti, che Giancarlo Nicoli ha ritenuto affidabili. L’accuratezza e la completezza delle stesse non può essere in nessun modo garantita. La presente pubblicazione viene pubblicata per meri fini di informazione ed illustrazione, non costituendo peraltro la stessa in alcun modo una proposta di conclusione di contratto o una sollecitazione all’acquisto o alla vendita di qualsiasi strumento finanziario. Il documento può essere riprodotto nella sua interezza. A tal proposito si chiede la cortesia di citare la fonte: www.scoprire.biz. La presente pubblicazione non si propone di sostituire il giudizio personale dei soggetti a cui si rivolge. Giancarlo Nicoli ha la facoltà di agire in base a/ovvero di servirsi di qualsiasi materiale sopra esposto e/o di qualsiasi informazione a cui tale materiale si ispira prima che lo stesso venga pubblicato e messo a disposizione dei lettori.
Giancarlo Nicoli può occasionalmente assumere posizioni lunghe o corte nei summenzionati prodotti finanziari.
I link eventualmente presenti sono stati verificati e risultano funzionanti al momento della pubblicazione del presente articolo.

di Giancarlo Nicoli

Stereotaxis Awarded $1.5 Million in Grants under the Qualifying Therapeutic Discovery Project Program

Filed Under Stereotaxis | Comments Off on Stereotaxis Awarded $1.5 Million in Grants under the Qualifying Therapeutic Discovery Project Program

From the press release.

ST. LOUIS, Nov. 4, 2010 /PRNewswire via COMTEX/ —

Stereotaxis, Inc. (Nasdaq: STXS) announced today that it has been awarded $1.5 million in grants under the Qualifying Therapeutic Discovery Project Program that was enacted under the Patient Protection and Affordable Care Act of 2010. The program targets projects that show potential to produce new therapies or medical technology that assists in the delivery or administration of therapeutics, addresses unmet medical needs and reduces the long-term growth of health care costs. Stereotaxis was awarded the grants for 2009 and 2010 projects related to the Company’s Niobe(R) Remote Magnetic Navigation System and Odyssey(TM) system, which are designed to provide a safer and more effective healthcare solution for treating heart arrhythmias using magnetic catheters within the heart.

“We are pleased that the U.S. Department of Health and Human Services recognizes the potential impact that Stereotaxis’ innovative technologies can have for patients suffering from diseases of the heart,” said Michael P. Kaminski, President and Chief Executive Officer of Stereotaxis. “These grants will allow Stereotaxis to further enhance and expand the capabilities of our technology in an effort to treat the most common type of heart arrhythmias, atrial fibrillation, as well as ventricular tachycardia and other cardiovascular disorders.”

About Stereotaxis

Stereotaxis designs, manufactures and markets an advanced cardiology instrument control system for use in a hospital’s interventional surgical suite to enhance the treatment of coronary artery disease and arrhythmias. The Niobe(R) Remote Magnetic Navigation System is designed to enable physicians to complete more complex interventional procedures by providing image guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. This is achieved using computer-controlled, externally applied magnetic fields that govern the motion of the working tip of the catheter or guidewire, resulting in improved navigation, shorter procedure time and reduced x-ray exposure.

Stereotaxis’ Odyssey(TM) portfolio of products provides an innovative enterprise solution for integrating, recording and networking interventional lab information within hospitals and around the world. Odyssey(TM) Vision integrates data for magnetic and standard interventional labs, enhancing the physician workflow through a consolidated display of multiple systems and eliminating the challenge of interacting simultaneously with many separate diagnostic systems. Odyssey(TM) Enterprise Cinema then captures a complete record of synchronized procedure data that can be viewed live or from a comprehensive archive of cases performed. Odyssey(TM) then enables hospitals to efficiently share live and recorded clinical data anywhere around the world to maximize referrals and promote collaboration.

The core components of the Stereotaxis systems have received regulatory clearance in the U.S., Europe, Canada and elsewhere. For more information, please visit www.stereotaxis.com and www.odysseyexperience.com.

This press release includes statements that may constitute “forward-looking” statements, usually containing the words “believe,” “estimate,” “project,” “expect” or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company’s products in the marketplace, the effect of global economic conditions on the ability and willingness of customers to purchase our systems and the timing of such purchases, competitive factors, changes resulting from the recently enacted healthcare reform in the U.S., including changes in government reimbursement procedures, dependence upon third-party vendors, timing of regulatory approvals, and other risks discussed in the Company’s periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that the Company will recognize revenue related to its purchase orders and other commitments in any particular period or at all because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company’s control. In addition, these orders and commitments may be revised, modified, delayed or canceled, either by their express terms, as a result of negotiations, or by overall project changes or delays.

SOURCE: Stereotaxis, Inc.

di Giancarlo Nicoli

Stereotaxis Reports Third Quarter Financial Results

Filed Under Stereotaxis | Comments Off on Stereotaxis Reports Third Quarter Financial Results

From the press release.

Total Revenue of $13.9 Million; Recurring Revenue up 24% to a Record $5.7 Million
Strong New Capital Orders Represent Increasing Penetration of Niobe and Odyssey
Gross Margin of 72.2%, Compared to 67.8% in Year Ago Quarter
Cash Burn Significantly Reduced to $1.7 Million

ST. LOUIS, Nov. 1, 2010 /PRNewswire via COMTEX/ —

Stereotaxis, Inc. (Nasdaq: STXS) announced today financial results for the quarter ended September 30, 2010 that were in line with the preliminary results reported on October 13, 2010. Third quarter 2010 results included record recurring revenue, strong gross margins, and reductions in both operating loss and net loss.

Revenue for the third quarter 2010 totaled $13.9 million, compared to $13.3 million in the third quarter 2009. As previously announced on October 13, 2010, revenue growth for the second half of 2010 is being impacted by installation delays in the third and fourth quarters. The Company recognized revenue of $5.5 million in Niobe(R) Magnetic Navigation Systems and $2.6 million in Odyssey(TM) systems in the third quarter 2010. Disposables, services and accessories revenue for the quarter ended September 30, 2010 increased 24% to a record $5.7 million from the recurring revenue reported for the year-ago quarter, and reflects continued growth in clinical procedures.

New capital orders for the quarter ended September 30, 2010 increased 94% to $12.2 million from the capital orders placed in the comparable period in 2009. Global orders for the Company’s Niobe Remote Magnetic Navigation System totaled $8.1 million, while Odyssey system orders increased over 140% to a record $4.1 million from the year ago period. New capital orders from North America orders were $6.3 million, or 52% of total orders in the third quarter of 2010.

“The strong momentum in new orders during the third quarter 2010 confirms that we continue to execute on our commercial strategy by further driving adoption of our innovative technology platforms, resulting in stronger reference sites,” said Michael P. Kaminski, President and Chief Executive Officer of Stereotaxis. “In particular, our Odyssey system continues to gain traction in standard electrophysiology labs in the U.S., driven by the demand to improve clinical data management and distribution capabilities. We remain confident in our near- and long-term growth potential, and believe the strong sustained trend in increased new capital orders combined with our focus on operational excellence will ultimately lead us to profitability.”

Third Quarter 2010 Financial Performance

Gross margin for the quarter ended September 30, 2010 increased 11% to $10.0 million from $9.0 million in the third quarter of 2009. This represented 72.2% of total revenue compared with 67.8% a year ago. Third quarter 2010 operating expenses totaled $13.6 million, compared to $13.2 million in the third quarter 2009. The combination of revenue growth, strong margins, operating expense control and tight cash management resulted in a significant reduction in cash burn to $1.7 million for the third quarter of 2010.

The operating loss for the third quarter 2010 was $(3.6) million, compared to an operating loss of $(4.2) million for the third quarter 2009. The net loss for the third quarter 2010 was $(5.1) million, or $(0.10) per share, compared to a net loss of $(5.8) million, or $(0.14) per share, reported for the third quarter 2009. Net loss for the third quarter 2010 included expense related to warrants issued in 2008 of $0.02 per share as a result of the increase in the Company’s stock price at September 30, 2010 versus June 30, 2010. Excluding the effect of the repricing of the warrants, the net loss in the third quarter 2010 was $(4.2) million, or $(0.08) per share. The weighted average shares for the third quarter of 2010 totaled 50.1 million compared with 42.0 million in the third quarter of last year. The increase was due in large part to the issuance of 7.5 million shares as part of the stock offering completed in October 2009.

At September 30, 2010, Stereotaxis had cash and cash equivalents of $21.8 million, compared to $22.0 million on June 30, 2010. Total debt was $26.5 million, including $17.0 million drawn against the Company’s $30 million line of credit.

Year-to-Date Financial Performance

Revenue for the first nine months of 2010 was $39.5 million, a 7% increase from the first nine months of 2009. Gross margin grew 13% to $27.8 million, or 70.4% of revenue, compared with $24.7 million, or 66.5% of revenue in the first nine months of the prior year. Operating expenses were $43.3 million for the first nine months of 2010 compared with $42.7 million in the same period of 2009. The operating loss decreased to $(15.5) million for the first nine months of 2010 compared with $(18.0) million for the comparable period of 2009. Cash burn for the first nine months of 2010, including payments against the Biosense Webster advance, was $16.0 million compared with $20.9 million in the first nine months of 2009. Stereotaxis has historically included the repayment of the Biosense advance as part of cash burn as operationally the advance is reduced by the earning of royalties. Of the $16.0 million in year-to-date cash burn, $3.8 million is repayment of Biosense debt.

2010 Financial Outlook

The Company updated its outlook for 2010 as follows:

  • New capital order growth in the range of 45%-50%
  • Total revenue growth in the high-single digit percentage range
  • Gross margins approaching 70%
  • Operating expenses between $59 million and $61 million

Conference Call Information

Stereotaxis will hold a conference call today, November 1, 2010 at 4:30 p.m. Eastern Time, to discuss third quarter 2010 results and operational highlights. The dial-in number for the conference call is 1-877-941-9205 for domestic participants and 1-480-629-9835 for international participants. An audio replay of the call will be available for seven days following the call, and can be accessed by dialing 1-800-406-7325 for domestic callers and 303-590-3030 for international callers, both using passcode 4377272#. The call will also be available on the Internet live and for 90 days thereafter at the following URL: http://www.videonewswire.com/event.asp?id=73566

About Stereotaxis

Stereotaxis designs, manufactures and markets an advanced cardiology instrument control system for use in a hospital’s interventional surgical suite to enhance the treatment of coronary artery disease and arrhythmias. The Niobe(R) Remote Magnetic Navigation System is designed to enable physicians to complete more complex interventional procedures by providing image guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. This is achieved using computer-controlled, externally applied magnetic fields that govern the motion of the working tip of the catheter or guidewire, resulting in improved navigation, shorter procedure time and reduced x-ray exposure.

Stereotaxis’ Odyssey(TM) portfolio of products provides an innovative enterprise solution for integrating, recording and networking interventional lab information within hospitals and around the world. Odyssey(TM) Vision integrates data for magnetic and standard interventional labs, enhancing the physician workflow through a consolidated display of multiple systems and eliminating the challenge of interacting simultaneously with many separate diagnostic systems. Odyssey(TM) Enterprise Cinema then captures a complete record of synchronized procedure data that can be viewed live or from a comprehensive archive of cases performed. Odyssey(TM) then enables hospitals to efficiently share live and recorded clinical data anywhere around the world to maximize referrals and promote collaboration.

The core components of the Stereotaxis systems have received regulatory clearance in the U.S., Europe, Canada and elsewhere.

This press release includes statements that may constitute “forward-looking” statements, usually containing the words “believe,” “estimate,” “project,” “expect” or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company’s products in the marketplace, the effect of global economic conditions on the ability and willingness of customers to purchase our systems and the timing of such purchases, competitive factors, changes resulting from the recently enacted healthcare reform in the U.S., including changes in government reimbursement procedures, dependence upon third-party vendors, timing of regulatory approvals, and other risks discussed in the Company’s periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that the Company will recognize revenue related to its purchase orders and other commitments in any particular period or at all because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company’s control. In addition, these orders and commitments may be revised, modified, delayed or canceled, either by their express terms, as a result of negotiations, or by overall project changes or delays.

STEREOTAXIS, INC.
BALANCE SHEETS
(Unaudited)
September 30,
2010
December 31,
2009
(Unaudited)
Assets
Current assets:
Cash and cash equivalents $ 21,792,728 $ 30,546,550
Accounts receivable, net of allowance of $311,680 and $322,463 in 2010 and 2009, respectively 10,909,844 11,152,648
Current portion of long-term receivables 63,800 66,800
Inventories 5,258,338 4,403,675
Prepaid expenses and other current assets 2,585,139 3,872,535
Total current assets 40,609,849 50,042,208
Property and equipment, net 4,108,137 4,790,310
Intangible assets 2,653,945 1,144,445
Long-term receivables 136,845 138,441
Other assets 5,113 5,112
Total assets $ 47,513,889 $ 56,120,516
Liabilities and stockholders’ equity
Current liabilities:
Current maturities of long-term debt $ 20,969,199 $ 3,333,333
Accounts payable 6,754,672 3,881,205
Accrued liabilities 7,840,984 8,615,287
Deferred contract revenue 7,172,396 7,191,492
Warrants 4,092,784 4,142,614
Total current liabilities 46,830,035 27,163,931
Long-term debt, less current maturities 5,555,754 20,346,655
Long-term deferred contract revenue 436,094 948,574
Other liabilities 11,462 20,013
Stockholders’ equity:
Preferred stock, par value $0.001; 10,000,000 shares authorized at 2010 and 2009; none outstanding at 2010 and 2009
Common stock, par value $0.001; 100,000,000 shares authorized at 2010 and 2009; 50,403,055 and 50,208,171 issued at 2010 and 2009, respectively 50,403 50,208
Additional paid-in capital 335,721,565 331,249,918
Treasury stock, 40,151 shares at 2010 and 2009 (205,999) (205,999)
Accumulated deficit (340,885,425) (323,452,784)
Total stockholders’ equity (5,319,456) 7,641,343
Total liabilities and stockholders’ equity $ 47,513,889 $ 56,120,516
STEREOTAXIS, INC.
STATEMENTS OF OPERATIONS
(Unaudited)
Three Months Ended
September 30,
Nine Months Ended
September 30,
2010 2009 2010 2009
Revenue
System $ 8,153,088 $ 8,671,302 $ 22,826,700 $ 23,694,613
Disposables, service and accessories 5,719,166 4,619,391 16,680,241 13,373,484
Total revenue 13,872,254 13,290,693 39,506,941 37,068,097
Cost of revenue
System 3,091,734 3,474,492 9,482,225 9,250,005
Disposables, service and accessories 763,348 811,089 2,219,680 3,162,142
Total cost of revenue 3,855,082 4,285,581 11,701,905 12,412,147
Gross margin 10,017,172 9,005,112 27,805,036 24,655,950
Operating expenses:
Research and development 2,868,426 3,302,008 9,595,972 10,247,877
Sales and marketing 7,269,005 6,290,814 22,410,734 21,424,796
General and administration 3,471,244 3,654,207 11,337,637 11,006,981
Total operating expenses 13,608,675 13,247,029 43,344,343 42,679,654
Operating loss (3,591,503) (4,241,917) (15,539,307) (18,023,704)
Other income/(expense) (920,222) (489,139) 49,830 66,507
Interest income 3,004 2,721 7,934 34,069
Interest expense (635,176) (1,085,408) (1,951,098) (2,860,479)
Net loss $ (5,143,897) $ (5,813,743) $ (17,432,641) $ (20,783,607)
Net loss per common share:
Basic and diluted $ (0.10) $ (0.14) $ (0.35) $ (0.50)
Weighted average shares used in computing net
loss per common share:
Basic and diluted 50,137,857 41,988,251 49,847,321 41,649,094

SOURCE: Stereotaxis, Inc.

di Giancarlo Nicoli

Stereotaxis Appoints Industry Veteran as Head of EMEA Sales and Operations

Filed Under Investimenti, Stereotaxis | Comments Off on Stereotaxis Appoints Industry Veteran as Head of EMEA Sales and Operations

From the press release.

ST. LOUIS, Oct. 28 /PRNewswire-FirstCall/ — Stereotaxis, Inc. (Nasdaq:STXSNews) announced today the appointment of Pierre Rivaux as Vice President, Europe, Middle East, Africa (EMEA) to lead the Company’s EMEA operations and sales efforts in continuing to drive increased capital sales and utilization of its Niobe® Remote Magnetic Navigation System and Odyssey™ system. Mr. Rivaux will report directly to Michael P. Kaminski, President and CEO of Stereotaxis.

“Pierre brings over 20 years of international sales and broad executive experience in the medical device industry that enhances Stereotaxis’ focus on driving future sales growth in Europe and other key international markets,” said Mr. Kaminski. “Pierre’s extensive experience in Europe, strong leadership and expertise in selling high-tech medical/surgical disposables and capital equipment, as well as in building effective international teams and global sales operations will be tremendous assets as we continue to execute on our strategy to drive commercial success of our innovative technology platforms, Niobe and Odyssey.”

Mr. Rivaux previously held various management positions at Intuitive Surgical, including Vice President of International Sales & Marketing, President and CEO of Intuitive Surgical SA France and CEO of Intuitive Surgical Sarl in Switzerland, where he was responsible for implementing a new sales, marketing and finance organization focused on Europe (direct and distribution), Middle East, Africa, India, Asia and Latin America. Prior to that, from 2000 to 2004, Mr. Rivaux held management positions across Europe with Tyco Healthcare, most recently serving as Vice President of Central Europe. He was also the President and CEO of Tyco Healthcare France. Before that, he worked at Kendall S.A., most recently as President, CEO and General Manager of Kendall Incontinence. He earned his graduate degree at the Lille Graduate School of Management in 1985.

About Stereotaxis

Stereotaxis designs, manufactures and markets an advanced cardiology instrument control system for use in a hospital’s interventional surgical suite to enhance the treatment of coronary artery disease and arrhythmias. The Niobe® Remote Magnetic Navigation System is designed to enable physicians to complete more complex interventional procedures by providing image guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. This is achieved using computer-controlled, externally applied magnetic fields that govern the motion of the working tip of the catheter or guidewire, resulting in improved navigation, shorter procedure time and reduced x-ray exposure.

Stereotaxis’ Odyssey™ portfolio of products provides an innovative enterprise solution for integrating, recording and networking interventional lab information within hospitals and around the world. Odyssey™ Vision integrates data for magnetic and standard interventional labs, enhancing the physician workflow through a consolidated display of multiple systems and eliminating the challenge of interacting simultaneously with many separate diagnostic systems. Odyssey™ Enterprise Cinema then captures a complete record of synchronized procedure data that can be viewed live or from a comprehensive archive of cases performed.  Odyssey™ then enables hospitals to efficiently share live and recorded clinical data anywhere around the world to maximize referrals and promote collaboration.

The core components of the Stereotaxis systems have received regulatory clearance in the U.S., Europe, Canada and elsewhere.

This press release includes statements that may constitute “forward-looking” statements, usually containing the words “believe,” “estimate,” “project,” “expect” or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company’s products in the marketplace, the effect of global  economic conditions on the ability and willingness of customers to purchase our systems and the timing of such purchases, competitive factors, changes resulting from the recently enacted healthcare reform in the U.S., including changes in government reimbursement procedures, dependence upon third-party vendors, timing of regulatory approvals, and other risks discussed in the Company’s periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that the Company will recognize revenue related to its purchase orders and other commitments in any particular period or at all because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company’s control. In addition, these orders and commitments may be revised, modified, delayed or canceled, either by their express terms, as a result of negotiations, or by overall project changes or delays.

Source: Stereotaxis, Inc.

di Giancarlo Nicoli

Stereotaxis Launches the Odyssey Interventional Network for Superior Online Cardiovascular Education and Training

Filed Under Investimenti, Stereotaxis | Comments Off on Stereotaxis Launches the Odyssey Interventional Network for Superior Online Cardiovascular Education and Training

From the press release.

ST. LOUIS, Oct. 20 /PRNewswire/ — Stereotaxis, Inc. (Nasdaq: STXS) announced today that it launched the Odyssey Interventional Network, a training and educational video sharing web portal for the global cardiovascular community. The portal will showcase innovative electrophysiology (EP) and interventional cardiology (IC) procedures from leading centers around the world. The Odyssey Interventional Network utilizes Stereotaxis’ state-of-the-art Odyssey technology platform to deliver a synchronized, high-definition view of all information available during a procedure. This allows specialists, referring doctors and patients an opportunity to virtually experience real interventional procedures and learn about the techniques of world-class clinical experts from the comfort of their home or office. The first online broadcast features a recorded EP procedure hosted by Dr. Andrea Natale, MD, FACC, FHRS and Dr. David Burkhardt, MD, FACC from the Texas Cardiac Arrhythmia Institute at St. David’s Medical Center in Austin, TX. They performed a case on a 50-year old patient with significant coronary artery disease who had received multiple shocks from his implantable defibrillator for ventricular tachycardia (VT) despite medical therapy. The patient was successfully treated during the procedure with the Stereotaxis Magnetic Navigation System as the doctors narrate the case. The Odyssey Interventional Network represents a paradigm shift for the delivery of medical education. Online procedures are often low-quality broadcasts with a limited view of the case. Procedures that are broadcast on the Odyssey Interventional Network feature a complete, synchronized view of the many systems in the interventional lab in high definition, preserving the fine details of diagnostic and imaging data. “Our Odyssey business is experiencing impressive growth as a workflow and information tool for cardiac catheterization labs (cath labs) and electrophysiology labs (EP labs) on a world-wide basis,” said Michael P. Kaminski, President and Chief Executive Officer of Stereotaxis. “In addition to its clear workflow and archiving advantages, many hospitals are acquiring the Odyssey solution to revolutionize their training and education programs. We believe that the Odyssey Interventional Network provides a major breakthrough in online education with a high definition panoramic view of lab information for an optimized learning experience.” The Odyssey Interventional Network is currently a complementary service requiring a simple user registration. It can be accessed through the company’s Odyssey business website, www.odysseyexperience.com, or the newly expanded company website, www.stereotaxis.com. Interested viewers can learn about upcoming cases at www.twitter.com/stereotaxis, or by joining Stereotaxis on Facebook. “The Odyssey Interventional Network addresses a significant unmet need in online clinical education for a broad audience,” added Mr. Kaminski. “Our unique clinical technology will leverage the new social and interactive Internet in this manner to better meet the needs of our customers and patients.” About Stereotaxis Stereotaxis designs, manufactures and markets an advanced cardiology instrument control system for use in a hospital’s interventional surgical suite to enhance the treatment of coronary artery disease and arrhythmias. The Niobe® Remote Magnetic Navigation System is designed to enable physicians to complete more complex interventional procedures by providing image guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. This is achieved using computer-controlled, externally applied magnetic fields that govern the motion of the working tip of the catheter or guidewire, resulting in improved navigation, shorter procedure time and reduced x-ray exposure. Stereotaxis’ Odyssey™ portfolio of products provides an innovative enterprise solution for integrating, recording and networking interventional lab information within hospitals and around the world. Odyssey™ Vision integrates data for magnetic and standard interventional labs, enhancing the physician workflow through a consolidated display of multiple systems and eliminating the challenge of interacting simultaneously with many separate diagnostic systems. Odyssey™ Enterprise Cinema then captures a complete record of synchronized procedure data that can be viewed live or from a comprehensive archive of cases performed. Odyssey™ then enables hospitals to efficiently share live and recorded clinical data anywhere around the world to maximize referrals and promote collaboration. The core components of the Stereotaxis systems have received regulatory clearance in the U.S., Europe, Canada and elsewhere. This press release includes statements that may constitute “forward-looking” statements, usually containing the words “believe,” “estimate,” “project,” “expect” or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company’s products in the marketplace, the effect of global economic conditions on the ability and willingness of customers to purchase our systems and the timing of such purchases, competitive factors, changes resulting from the recently enacted healthcare reform in the U.S., including changes in government reimbursement procedures, dependence upon third-party vendors, timing of regulatory approvals, and other risks discussed in the Company’s periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that the Company will recognize revenue related to its purchase orders and other commitments in any particular period or at all because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company’s control. In addition, these orders and commitments may be revised, modified, delayed or canceled, either by their express terms, as a result of negotiations, or by overall project changes or delays. CONTACT: Company, Dan Johnston, Chief Financial Officer of Stereotaxis, Inc., +1-314-678-6007; or Investors, Doug Sherk & Gregory Gin, +1-415-896-6820, or Media, Steve DiMattia, +1-646-201-5445, all of EVC Group, Inc., for Stereotaxis, Inc.

Source: Stereotaxis, Inc.

di Giancarlo Nicoli

Stereotaxis Announces Third Quarter 2010 Capital Orders of $12.2 Million, Up 94 Percent Year-to-Year

Filed Under Investimenti, Stereotaxis | Comments Off on Stereotaxis Announces Third Quarter 2010 Capital Orders of $12.2 Million, Up 94 Percent Year-to-Year

From the press release.

Odyssey Orders Grow 140% from Third Quarter 2009
Increasing 2010 New Capital Order Guidance; Reducing 2010 Revenue Guidance

ST. LOUIS, Oct 13, 2010 /PRNewswire via COMTEX/ —

Stereotaxis, Inc. (Nasdaq: STXS) announced today that the new capital order momentum continued to build in the third quarter of 2010. The Company generated new capital orders of $12.2 million, which is a 94% increase over the capital orders placed during the third quarter of 2009, and a 19% increase over the second quarter of 2010. Globally, orders for the Company’s Niobe(R) Remote Magnetic Navigation System totaled $8.1 million, while Odyssey(TM) system orders increased over 140% from the year ago period to a record $4.1 million. As a result of the strong third quarter performance, the Company now expects capital orders for 2010 to increase by approximately 45-50% over 2009 levels. Previously, the Company had guided new orders for 2010 to increase by over 40%.

Stereotaxis also reported that revenue growth for the second half of 2010 is being impacted by installation delays in the third and fourth quarters. As a result, revenue in the third quarter of 2010 is now expected to be in the range of $13.5 million to $14.0 million, compared to $13.3 million in the third quarter 2009. Full year revenue is now expected to grow in the high single digit percentage range versus 2009 revenue of $51.1 million. Previously, the Company had guided revenue for 2010 to increase in the mid-twenty percent range.

Contributing to the aforementioned delays, the Company has been notified by an imaging partner that, due to production constraints, they will not install any magnetically compatible x-ray systems from the fourth quarter of 2010 until the second quarter of 2011. In the fourth quarter, one system is known to be impacted and one to two other customers may switch to a different imaging partner which may cause Niobe installation delays. In addition to the fourth quarter 2010 impact, it is expected that a small number of Niobe installations will be also be delayed from the first to the second quarter of 2011.

“Naturally we are disappointed that our near term revenue growth is less than expected; nevertheless, we are pleased that the leading indicator of success in the marketplace, new capital orders, continues to strengthen and reflect broad geographic and product line commercial success. It is important to note that the near term delay in revenue growth is not the result of lost business, but rather the timing of system placements. Ultimately, we believe that the strengthening of our order backlog will provide us with a larger pool of revenue opportunities resulting in a smaller impact from installation timing shifts like we are reporting today,” said Michael P. Kaminski, President and Chief Executive Officer of Stereotaxis.

“The strength in new orders in the third quarter of 2010 and what we expect to book in the fourth quarter of 2010 confirms that we are making strong progress in our key initiatives of driving stronger Niobe reference sites and growing our Odyssey business. In addition, we expect a record low cash burn for the third quarter of 2010 of less than $2.0 million, which is a combination of strong margins and operational expense control. We look forward to expanding on the state of business during our third quarter call during the first week of November,” Kaminski continued.

About Stereotaxis

Stereotaxis designs, manufactures and markets an advanced cardiology instrument control system for use in a hospital’s interventional surgical suite to enhance the treatment of coronary artery disease and arrhythmias. The Niobe(R) Remote Magnetic Navigation System is designed to enable physicians to complete more complex interventional procedures by providing image guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. This is achieved using computer-controlled, externally applied magnetic fields that govern the motion of the working tip of the catheter or guidewire, resulting in improved navigation, shorter procedure time and reduced x-ray exposure.

Stereotaxis’ Odyssey(TM) portfolio of products provides an innovative enterprise solution for integrating, recording and networking interventional lab information within hospitals and around the world. Odyssey(TM) Vision integrates data for magnetic and standard interventional labs, enhancing the physician workflow through a consolidated display of multiple systems and eliminating the challenge of interacting simultaneously with many separate diagnostic systems. Odyssey(TM) Enterprise Cinema then captures a complete record of synchronized procedure data that can be viewed live or from a comprehensive archive of cases performed. Odyssey(TM) then enables hospitals to efficiently share live and recorded clinical data anywhere around the world to maximize referrals and promote collaboration.

The core components of the Stereotaxis systems have received regulatory clearance in the U.S., Europe, Canada and elsewhere.

This press release includes statements that may constitute “forward-looking” statements, usually containing the words “believe,” “estimate,” “project,” “expect” or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company’s products in the marketplace, the effect of global economic conditions on the ability and willingness of customers to purchase our systems and the timing of such purchases, competitive factors, changes resulting from the recently enacted healthcare reform in the U.S., including changes in government reimbursement procedures, dependence upon third-party vendors, timing of regulatory approvals, and other risks discussed in the Company’s periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that the Company will recognize revenue related to its purchase orders and other commitments in any particular period or at all because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company’s control. In addition, these orders and commitments may be revised, modified, delayed or canceled, either by their express terms, as a result of negotiations, or by overall project changes or delays.

SOURCE: Stereotaxis, Inc.

di Giancarlo Nicoli

Stereotaxis Achieves Intellectual Property Milestone With 100th U.S. Patent

Filed Under Investimenti, Stereotaxis | Comments Off on Stereotaxis Achieves Intellectual Property Milestone With 100th U.S. Patent

From the press release.

Commitment to Innovation Expands Company Leadership Position in Interventional Care

ST. LOUIS, Sept 20, 2010 /PRNewswire via COMTEX/ —

Stereotaxis, Inc. (Nasdaq: STXS) today announced that the U.S. Patent and Trademark Office granted the Company its 100th patent, a major intellectual property milestone. The 100th patent, U.S. patent No. 7,772,950, covers the “Method and Apparatus for Dynamic Magnetic Field Control Using Multiple Magnets.” The 100th patent reflects Stereotaxis’ ongoing commitment to innovate and protect its leading position in robotic solutions for interventional medicine.

“Our 100th patent represents a significant milestone in Stereotaxis’ drive to protect shareholder value and deliver innovative technologies that improve treatment options for patients with cardiovascular disease,” said Michael P. Kaminski, President and Chief Executive Officer. “Our strong intellectual property position enables the delivery of measurable clinical benefits across the broadest range of cardiovascular, neurovascular, peripheral vascular and other interventional applications, including treatment of ventricular tachycardia with high levels of acute success.”

For more than 15 years, Stereotaxis has built a robust intellectual property portfolio, which includes these 100 issued patents and over 100 additional patent applications in process for approval. Stereotaxis’ extensive U.S. patent portfolio is supplemented by more than 30 non-U.S. patents and patent applications. The Company anticipates doubling the number of non-U.S. patents in the next few months as patents issue on its Niobe(R) Magnetic Navigation System. The patents issued to date include remote/robotic assisted cardiology procedures, diagnostic integration, therapeutic devices, software automation, and information technology for patient/case management.

For the past two years, Stereotaxis ranked in the top 10 of IEEE Spectrum’s Patent Power Scorecard, a rating of the world’s most valuable patent portfolios. Many of Stereotaxis’ 100 U.S. patents have been the basis for new product solutions, while others have been strategically leveraged in alliances with global giants in the area of cardiology.

About Stereotaxis

Stereotaxis designs, manufactures and markets an advanced cardiology instrument control system for use in a hospital’s interventional surgical suite to enhance the treatment of arrhythmias and coronary artery disease. The Stereotaxis system is designed to enable physicians to complete more complex interventional procedures by providing image guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. This is achieved using computer-controlled, externally applied magnetic fields that govern the motion of the working tip of the catheter or guidewire, resulting in improved navigation, shorter procedure time and reduced x-ray exposure. The unparalleled clinical capability of Stereotaxis has driven more than 130 hospitals to adopt magnetic navigation for a growing number of complex ablation cases in all four chambers of the heart. Stereotaxis technology is now installed and used by 9 out of the Top 10 Best U.S. Heart Hospitals as ranked by U.S. News and World Report, and more than one third of the EP academic training centers in the United States have included Stereotaxis into their arrhythmia treatment laboratories. The core components of the Stereotaxis system have received regulatory clearance in the U.S., Europe, Canada and elsewhere.

About Odyssey

The Odyssey portfolio of products provides an innovative enterprise solution for integrating, recording and networking interventional lab information around the world. Odyssey Vision standardizes data integration for magnetic and standard interventional labs by enhancing the physician workflow through a consolidated display of multiple systems and eliminating the challenge of interacting simultaneously with many separate diagnostic systems. Odyssey Enterprise Cinema then captures a complete record of synchronized procedure data that can be viewed live or from a comprehensive archive of cases performed. Through its proprietary data compression technology, Cinema enables sharing of live and recorded procedure data via a laptop anywhere over a secure high speed Internet connection. Hospitals can also share procedures with other institutions using Odyssey Network Connect providing a global forum for defining clinical best practices across a broad spectrum of medical procedures.

This press release includes statements that may constitute “forward-looking” statements, usually containing the words “believe,” “estimate,” “project,” “expect” or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance for the Company’s products in the marketplace, the effect of global credit and economic conditions on the ability and willingness of customers to purchase our systems, competitive factors, changes in government reimbursement procedures, dependence upon third-party vendors, timing of regulatory approval and return of the irrigated catheter to the market, and other risks discussed in the Company’s periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that the Company will recognize revenue related to its purchase orders and other commitments in any particular period or at all because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company’s control. In addition, these orders and commitments may be revised, modified or canceled, either by their express terms, as a result of negotiations, or by project changes or delays.

SOURCE: Stereotaxis, Inc.

Next Page →

%d bloggers like this: